Navigation Links
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association

S) at 12 weeks compared to baseline. Secondary efficacy endpoints included changes in IPSS Quality of Life (QoL), patients with >/= 30% and >/= 40% improvement in IPSS, uroflow values (Qmax), PVR and prostate volume. Safety analysis included changes in sexual function (IIEF-5), treatment emergent AEs, lab values (including testosterone, PSA) and vital signs. Mean age was 69.1 (range 52 - 85), IPSS 19.8, Qmax 9.7 mL/sec and prostate size (cm3) 41.6 at baseline.

The effects developed rapidly, with noticeable activity at four weeks from starting treatment, were maximal at 12-16 weeks, and persisted for the entire six-month observation period. At 12 weeks all ozarelix-treated groups showed improvement with the greatest improvement in the 15mg +15mg group. Change from baseline vs. placebo in IPSS was 8.5; peak urine flow change from baseline vs. placebo was 4.7; T levels declined transiently, and returned to baseline in most subjects by 4 weeks and all subjects by 6 weeks following dosing. Based on IIEF, there was no effect seen on erectile function.

Ozarelix was well tolerated and demonstrated statistically significant and clinically meaningful efficacy in the treatment of LUTS secondary to BPH. Serious Adverse Events were reported in 4 patients but were not considered treatment related. No systemic allergic reactions were seen, and the injections were well tolerated.

About Ozarelix and Development Alliance with AEterna Zentaris

Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist administered as an intramuscular injection. In August 2004, Spectrum received an exclusive license from AEterna Zentaris to develop and market ozarelix for all potential indications in North America (including Canada and Mexico) and India.

In addition, Spectrum will receive 50 percent of any upfront and milestone payments, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/22/2015)... Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... on Omega-3 therapies for cardiovascular disease and overall health is ... accomplishments in 2014 and its outlook for 2015 from the ... Shareholders, We would like to take this opportunity ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015  Profil Institute for ... on diabetes and obesity, announced today a new textbook,  ... Development,  published by Springer, a leading global scientific publisher. ... analyze and illustrate techniques for use in early phase ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x3hp3g/microbiology ... "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application ... report to their offering. Clinical ... for the detection of infectious diseases. The respiratory ...
Breaking Medicine Technology:Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Scientific Corporation (NYSE: BSX ) today announced ... District of Delaware found that Cordis Corporation owed Boston ... which covers intellectual property associated with coronary stent technologies. ... $1 million in reasonable royalties to Boston Scientific. ...
... 2011 Applied Isotope Technologies (AIT), a company ... environmental, healthcare and industrial segments by applying its ... established operations in a 1,500 square foot analytical ... life sciences campus on the south side of ...
Cached Medicine Technology:Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation 2Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation 3Applied Isotope Technologies Opens New Facility in PLSG Life Sciences Campus 2
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding dresses ... latest collection of wedding dresses , and launches a site-wide ... wedding dress on your big day; the wedding gown is ... wants to find the most suitable wedding dress. Now, we ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... MILWAUKEE, Jan. 5 One in ten people will suffer ... be diagnosed with epilepsy.,Medication will help approximately two-thirds of the ... there are other alternatives. , "Epilepsy ... at Marquette University . "I would have seizures ...
... 5 ev3 Inc. (Nasdaq: EVVV ) today ... scheduled to present at the 27th Annual J.P. Morgan Healthcare ... 2009 at the Westin St. Francis Hotel located at 335 ... the investors, section of the ev3 Web site at ...
... For those looking to go beyond a bachelor,s degree ... (UIC) College of Nursing (CON) offers a variety ... and nurses hoping to apply for the next semester should ... ."Whether you,re interested in a nursing career in public health, ...
... Governor Edward G. Rendell expressed disappointment today that ... their waning days -- would push forward a ... a woman,s access to medical treatments. "I,m very ... midnight regulation that establishes a ,refusal clause, rule ...
... Peake: Entire Health Care System More EffectiveWASHINGTON, Jan. 5 ... and avoid hospitalization by using special technology provided by ... according to a recent study. "The study showed ... it improves patients, access to care and is easy ...
... Care Action Network (SCAN(R)) Health Plan Arizona, a nonprofit Medicare ... to train more than 60 seasoned van drivers about what ... a senior." SCAN has been focused on the unique needs ... to enhancing awareness and skills in the community in dealing ...
Cached Medicine News:Health News:Ending Epileptic Seizures 2Health News:UIC College of Nursing Now Accepting Applications for Graduate Programs 2Health News:UIC College of Nursing Now Accepting Applications for Graduate Programs 3Health News:Gov. Rendell Expresses Disappointment with Bush Administration's Last-Minute Regulation Limiting Patient Care 2Health News:Gov. Rendell Expresses Disappointment with Bush Administration's Last-Minute Regulation Limiting Patient Care 3Health News:VA Data Show Home Health Technology Improves Access to Care 2Health News:SCAN Health Plan Arizona Helps Drivers Understand the Challenges of Aging 2Health News:SCAN Health Plan Arizona Helps Drivers Understand the Challenges of Aging 3
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
Inquire...
... assay for the detection of the APC ... to activated protein C (APC). The test ... the anticoagulant function in vivo and provides ... inherited and acquired APC resistance. Detects the ...
Inquire...
Medicine Products: